Reuters logo
Bristol-Myers, Daiichi Sankyo to test combo therapy for breast, bladder cancers
August 28, 2017 / 8:42 PM / 3 months ago

Bristol-Myers, Daiichi Sankyo to test combo therapy for breast, bladder cancers

Aug 28 (Reuters) - Bristol-Myers Squibb Co and Daiichi Sankyo said they would collaborate on a clinical trial to evaluate a combination of Bristol-Myers’ immuno-oncology drug, Opdivo, with the Japanese company’s experimental drug in patients with breast and bladder cancers.

The companies said the study in patients with HER2-expressing advanced breast and bladder cancer is expected to begin enrollment in the first quarter of 2018. (Reporting by Manas Mishra in Bengaluru; Editing by Anil D‘Silva)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below